NASDAQ:VRNA - Verona Pharma Stock Price, Price Target & More

$16.61 -0.19 (-1.13 %)
(As of 04/23/2018 03:21 AM ET)
Previous Close$16.61
Today's Range$16.61 - $16.80
52-Week Range$10.44 - $25.55
Volume2,204 shs
Average Volume25,009 shs
Market Capitalization$218.04 million
P/E Ratio-6.89
Dividend YieldN/A
BetaN/A

About Verona Pharma (NASDAQ:VRNA)

Verona Pharma logoVerona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and IIa clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease and cystic fibrosis. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

Receive VRNA News and Ratings via Email

Sign-up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VRNA
CUSIPN/A
Phone44-20-3283-4200

Debt

Debt-to-Equity RatioN/A
Current Ratio10.14%
Quick Ratio10.14%

Price-To-Earnings

Trailing P/E Ratio-6.89
Forward P/E Ratio-5.89
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$7.84 per share
Price / Book2.12

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees15
Outstanding Shares13,130,000

How to Become a New Pot Stock Millionaire

Verona Pharma (NASDAQ:VRNA) Frequently Asked Questions

What is Verona Pharma's stock symbol?

Verona Pharma trades on the NASDAQ under the ticker symbol "VRNA."

How were Verona Pharma's earnings last quarter?

Verona Pharma (NASDAQ:VRNA) posted its earnings results on Tuesday, February, 27th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.19. View Verona Pharma's Earnings History.

What price target have analysts set for VRNA?

5 Wall Street analysts have issued 1 year price targets for Verona Pharma's shares. Their forecasts range from $25.00 to $55.00. On average, they expect Verona Pharma's share price to reach $34.60 in the next year. View Analyst Ratings for Verona Pharma.

Who are some of Verona Pharma's key competitors?

Who are Verona Pharma's key executives?

Verona Pharma's management team includes the folowing people:
  • Dr. Jan-Anders Karlsson, Chief Exec. Officer & Exec. Director (Age 63)
  • Mr. Piers John Morgan MA, ACA, Chief Financial Officer (Age 52)
  • Ms. Claire Louise Poll, Legal Counsel (Age 51)
  • Dr. Peter Spargo Ph.D., Sr. VP of CMC (Age 56)
  • Dr. Kenneth Newman, Chief Medical Officer (Age 60)

When did Verona Pharma IPO?

(VRNA) raised $61 million in an initial public offering (IPO) on Thursday, April 27th 2017. The company issued 4,500,000 shares at a price of $13.49 per share. Jefferies and Stifel served as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers.

Has Verona Pharma been receiving favorable news coverage?

News coverage about VRNA stock has been trending somewhat negative this week, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Verona Pharma earned a media sentiment score of -0.06 on Accern's scale. They also gave news coverage about the company an impact score of 45.64 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

How do I buy shares of Verona Pharma?

Shares of VRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Verona Pharma's stock price today?

One share of VRNA stock can currently be purchased for approximately $16.61.

How big of a company is Verona Pharma?

Verona Pharma has a market capitalization of $218.04 million. The company earns $-26,410,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Verona Pharma employs 15 workers across the globe.

How can I contact Verona Pharma?

Verona Pharma's mailing address is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. The company can be reached via phone at 44-20-3283-4200 or via email at [email protected]


MarketBeat Community Rating for Verona Pharma (VRNA)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  99 (Vote Outperform)
Underperform Votes:  61 (Vote Underperform)
Total Votes:  160
MarketBeat's community ratings are surveys of what our community members think about Verona Pharma and other stocks. Vote "Outperform" if you believe VRNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRNA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Verona Pharma (NASDAQ:VRNA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Verona Pharma in the last 12 months. Their average twelve-month price target is $34.60, suggesting that the stock has a possible upside of 108.31%. The high price target for VRNA is $55.00 and the low price target for VRNA is $25.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $34.60$28.00$26.75$26.75
Price Target Upside: 108.31% upside86.67% upside135.06% upside60.56% upside

Verona Pharma (NASDAQ:VRNA) Consensus Price Target History

Price Target History for Verona Pharma (NASDAQ:VRNA)

Verona Pharma (NASDAQ:VRNA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/27/2018WedbushReiterated RatingOutperform -> Outperform$48.00 -> $55.00HighView Rating Details
3/26/2018SunTrust BanksBoost Price TargetBuy -> Buy$26.00 -> $37.00HighView Rating Details
3/2/2018Stifel NicolausSet Price TargetBuy$25.00LowView Rating Details
2/20/2018Berenberg BankInitiated CoverageBuy -> Buy$30.00HighView Rating Details
5/22/2017Jefferies GroupReiterated RatingBuy$26.00HighView Rating Details
(Data available from 4/23/2016 forward)

Earnings

Verona Pharma (NASDAQ:VRNA) Earnings History and Estimates Chart

Earnings by Quarter for Verona Pharma (NASDAQ:VRNA)

Verona Pharma (NASDAQ:VRNA) Earnings Estimates

2018 EPS Consensus Estimate: ($2.75)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($1.13)($0.44)($0.71)
Q2 20183($1.13)($0.46)($0.72)
Q3 20183($0.76)($0.48)($0.63)
Q4 20183($0.84)($0.50)($0.69)

Verona Pharma (NASDAQ VRNA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018n/a($0.83)($0.64)ViewN/AView Earnings Details
11/7/2017Q3 2017($0.51)($0.91)ViewN/AView Earnings Details
8/8/20176/30/2017($0.28)($0.37)ViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Verona Pharma (NASDAQ:VRNA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Verona Pharma (NASDAQ VRNA) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 44.23%
Insider Trading History for Verona Pharma (NASDAQ:VRNA)
Insider Trading History for Verona Pharma (NASDAQ:VRNA)

Verona Pharma (NASDAQ VRNA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Verona Pharma (NASDAQ VRNA) News Headlines

Source:
DateHeadline
Zacks Investment Research Upgrades Verona Pharma plc - American Depositary Share (VRNA) to "Buy"Zacks Investment Research Upgrades Verona Pharma plc - American Depositary Share (VRNA) to "Buy"
www.americanbankingnews.com - April 16 at 1:54 PM
Verona Pharma Announces Departure of Chief Medical OfficerVerona Pharma Announces Departure of Chief Medical Officer
finance.yahoo.com - April 11 at 10:23 AM
Verona Pharma plc - American Depositary Share (VRNA) Receives Consensus Rating of "Buy" from BrokeragesVerona Pharma plc - American Depositary Share (VRNA) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - April 11 at 9:57 AM
-$0.63 EPS Expected for Verona Pharma plc - American Depositary Share (VRNA) This Quarter-$0.63 EPS Expected for Verona Pharma plc - American Depositary Share (VRNA) This Quarter
www.americanbankingnews.com - April 11 at 5:49 AM
The Zacks Analyst Blog Highlights: Verona, Squibb, Protagonist and AmgenThe Zacks Analyst Blog Highlights: Verona, Squibb, Protagonist and Amgen
finance.yahoo.com - March 29 at 10:07 AM
Verona Pharma plc - American Depositary Share (VRNA) Receives "Outperform" Rating from WedbushVerona Pharma plc - American Depositary Share (VRNA) Receives "Outperform" Rating from Wedbush
www.americanbankingnews.com - March 27 at 10:07 AM
Verona Pharma plc - American Depositary Share (VRNA) PT Raised to $37.00Verona Pharma plc - American Depositary Share (VRNA) PT Raised to $37.00
www.americanbankingnews.com - March 26 at 5:24 PM
Verona Pharma Reports Positive Top-Line Data from Phase 2b Clinical Trial of RPL554 for Maintenance Treatment of COPDVerona Pharma Reports Positive Top-Line Data from Phase 2b Clinical Trial of RPL554 for Maintenance Treatment of COPD
finance.yahoo.com - March 26 at 10:11 AM
Verona Pharma plc - American Depositary Share (VRNA) Expected to Announce Earnings of -$0.63 Per ShareVerona Pharma plc - American Depositary Share (VRNA) Expected to Announce Earnings of -$0.63 Per Share
www.americanbankingnews.com - March 25 at 8:50 AM
Verona Pharma plc - American Depositary Share (VRNA) Given Average Recommendation of "Buy" by AnalystsVerona Pharma plc - American Depositary Share (VRNA) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - March 17 at 9:48 AM
Verona Pharma to Present at Upcoming Healthcare Investor ConferencesVerona Pharma to Present at Upcoming Healthcare Investor Conferences
finance.yahoo.com - March 15 at 9:37 AM
Grant of Options and RSUs and PDMR DealingsGrant of Options and RSUs and PDMR Dealings
finance.yahoo.com - March 9 at 10:20 AM
Verona Pharma plc : Grant of Options and RSUs and PDMR DealingsVerona Pharma plc : Grant of Options and RSUs and PDMR Dealings
finance.yahoo.com - March 9 at 10:20 AM
Verona Pharma plc : 1st Quarter ResultsVerona Pharma plc : 1st Quarter Results
finance.yahoo.com - March 8 at 10:06 AM
Verona Pharma plc - American Depositary Share (VRNA) PT Set at $25.00 by Stifel NicolausVerona Pharma plc - American Depositary Share (VRNA) PT Set at $25.00 by Stifel Nicolaus
www.americanbankingnews.com - March 2 at 6:24 PM
Verona Pharma Reports Positive Top-Line Data from Phase 2a Trial with RPL554 in Cystic Fibrosis PatientsVerona Pharma Reports Positive Top-Line Data from Phase 2a Trial with RPL554 in Cystic Fibrosis Patients
finance.yahoo.com - March 2 at 9:33 AM
Verona Pharma plc - American Depositary Share (VRNA) to Post Q1 2018 Earnings of ($1.13) Per Share, SunTrust Banks ForecastsVerona Pharma plc - American Depositary Share (VRNA) to Post Q1 2018 Earnings of ($1.13) Per Share, SunTrust Banks Forecasts
www.americanbankingnews.com - March 2 at 9:10 AM
Research Analysts Offer Predictions for Verona Pharma plc - American Depositary Shares Q3 2018 Earnings (VRNA)Research Analysts Offer Predictions for Verona Pharma plc - American Depositary Share's Q3 2018 Earnings (VRNA)
www.americanbankingnews.com - March 1 at 11:08 AM
Jefferies Group Weighs in on Verona Pharma plc - American Depositary Shares Q1 2018 Earnings (VRNA)Jefferies Group Weighs in on Verona Pharma plc - American Depositary Share's Q1 2018 Earnings (VRNA)
www.americanbankingnews.com - February 28 at 8:06 AM
Verona Pharma plc - American Depositary Share (VRNA) Releases  Earnings Results, Beats Estimates By $0.19 EPSVerona Pharma plc - American Depositary Share (VRNA) Releases Earnings Results, Beats Estimates By $0.19 EPS
www.americanbankingnews.com - February 27 at 5:50 PM
Verona Pharma plc ("Verona Pharma" or the "Company") Reports Operational Update and Financial Results for Full Year Ended December 31, 2017Verona Pharma plc ("Verona Pharma" or the "Company") Reports Operational Update and Financial Results for Full Year Ended December 31, 2017
finance.yahoo.com - February 27 at 9:42 AM
Verona Pharma plc - American Depositary Share (VRNA) Scheduled to Post Quarterly Earnings on TuesdayVerona Pharma plc - American Depositary Share (VRNA) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - February 23 at 5:26 PM
Verona Pharma plc - American Depositary Share (VRNA) Receives Consensus Recommendation of "Buy" from AnalystsVerona Pharma plc - American Depositary Share (VRNA) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - February 20 at 4:46 PM
Verona Pharma plc - American Depositary Share (VRNA) Coverage Initiated at Berenberg BankVerona Pharma plc - American Depositary Share (VRNA) Coverage Initiated at Berenberg Bank
www.americanbankingnews.com - February 20 at 3:07 PM
Verona Pharma plc - American Depositary Share Expected to Earn FY2022 Earnings of ($5.00) Per Share (VRNA)Verona Pharma plc - American Depositary Share Expected to Earn FY2022 Earnings of ($5.00) Per Share (VRNA)
www.americanbankingnews.com - February 16 at 4:16 PM
 Verona Pharma plc - American Depositary Share (VRNA) Receives Average Recommendation of "Strong Buy" from Brokerages Verona Pharma plc - American Depositary Share (VRNA) Receives Average Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - February 16 at 10:22 AM
Wedbush Reiterates "Outperform" Rating for Verona Pharma plc - American Depositary Share (VRNA)Wedbush Reiterates "Outperform" Rating for Verona Pharma plc - American Depositary Share (VRNA)
www.americanbankingnews.com - February 13 at 8:08 PM
 Analysts Set $26.75 Price Target for Verona Pharma plc - American Depositary Share (VRNA) Analysts Set $26.75 Price Target for Verona Pharma plc - American Depositary Share (VRNA)
www.americanbankingnews.com - February 9 at 9:10 PM
 Brokerages Anticipate Verona Pharma plc - American Depositary Share (VRNA) Will Announce Earnings of -$0.83 Per Share Brokerages Anticipate Verona Pharma plc - American Depositary Share (VRNA) Will Announce Earnings of -$0.83 Per Share
www.americanbankingnews.com - February 2 at 2:22 PM
Zacks: Analysts Set $26.75 Target Price for Verona Pharma plc - American Depositary Share (VRNA)Zacks: Analysts Set $26.75 Target Price for Verona Pharma plc - American Depositary Share (VRNA)
www.americanbankingnews.com - January 25 at 11:40 AM
 Verona Pharma plc - American Depositary Share (VRNA) Given $26.75 Consensus Target Price by Analysts Verona Pharma plc - American Depositary Share (VRNA) Given $26.75 Consensus Target Price by Analysts
www.americanbankingnews.com - January 9 at 7:58 AM
 Brokerages Set $26.75 Price Target for Verona Pharma plc - American Depositary Share (VRNA) Brokerages Set $26.75 Price Target for Verona Pharma plc - American Depositary Share (VRNA)
www.americanbankingnews.com - December 25 at 8:26 AM
 Verona Pharma plc - American Depositary Share (VRNA) Given Consensus Recommendation of "Strong Buy" by Brokerages Verona Pharma plc - American Depositary Share (VRNA) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - December 21 at 5:40 PM
Verona Pharma PLC American Depositary Share (VRNA) Stock Rating Reaffirmed by WedbushVerona Pharma PLC American Depositary Share (VRNA) Stock Rating Reaffirmed by Wedbush
www.americanbankingnews.com - December 8 at 4:40 PM
Zacks: Brokerages Set $26.75 Target Price for Verona Pharma PLC American Depositary Share (VRNA)Zacks: Brokerages Set $26.75 Target Price for Verona Pharma PLC American Depositary Share (VRNA)
www.americanbankingnews.com - December 5 at 7:50 PM
Verona Pharma plc : PDMR DealingVerona Pharma plc : PDMR Dealing
finance.yahoo.com - November 30 at 9:09 AM
Zacks: Brokerages Set $26.75 Price Target for Verona Pharma PLC American Depositary Share (VRNA)Zacks: Brokerages Set $26.75 Price Target for Verona Pharma PLC American Depositary Share (VRNA)
www.americanbankingnews.com - November 19 at 1:38 PM
Verona Pharma PLC American Depositary Share (VRNA) to Post FY2017 Earnings of ($2.91) Per Share, Jefferies Group ForecastsVerona Pharma PLC American Depositary Share (VRNA) to Post FY2017 Earnings of ($2.91) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - November 10 at 12:41 PM
Verona Pharma PLC American Depositary Share (VRNA) Downgraded by Zacks Investment ResearchVerona Pharma PLC American Depositary Share (VRNA) Downgraded by Zacks Investment Research
www.americanbankingnews.com - November 10 at 8:37 AM
Verona Pharma PLC American Depositary Share to Post FY2020 Earnings of $4.31 Per Share, Jefferies Group Forecasts (VRNA)Verona Pharma PLC American Depositary Share to Post FY2020 Earnings of $4.31 Per Share, Jefferies Group Forecasts (VRNA)
www.americanbankingnews.com - November 9 at 4:02 PM
FY2017 Earnings Estimate for Verona Pharma PLC American Depositary Share Issued By SunTrust Banks (VRNA)FY2017 Earnings Estimate for Verona Pharma PLC American Depositary Share Issued By SunTrust Banks (VRNA)
www.americanbankingnews.com - November 9 at 6:22 AM
Zacks: Verona Pharma PLC American Depositary Share (VRNA) Given Consensus Recommendation of "Strong Buy" by AnalystsZacks: Verona Pharma PLC American Depositary Share (VRNA) Given Consensus Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - November 4 at 3:38 AM
Should You Buy Verona Pharma plc (AIM:VRP)?Should You Buy Verona Pharma plc (AIM:VRP)?
finance.yahoo.com - October 28 at 8:23 AM
[$$] Small-cap focus: UK life sciences groups look across Atlantic[$$] Small-cap focus: UK life sciences groups look across Atlantic
finance.yahoo.com - October 20 at 4:30 PM
 Verona Pharma PLC American Depositary Share (VRNA) Receives Average Recommendation of "Strong Buy" from Brokerages Verona Pharma PLC American Depositary Share (VRNA) Receives Average Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - October 20 at 6:44 AM
Verona Pharma PLC American Depositary Shares Lock-Up Period To End  on October 24th (NASDAQ:VRNA)Verona Pharma PLC American Depositary Share's Lock-Up Period To End on October 24th (NASDAQ:VRNA)
www.americanbankingnews.com - October 17 at 1:06 AM
Zacks: Verona Pharma PLC American Depositary Share (VRNA) Given $26.75 Average Price Target by BrokeragesZacks: Verona Pharma PLC American Depositary Share (VRNA) Given $26.75 Average Price Target by Brokerages
www.americanbankingnews.com - October 5 at 12:20 PM
Verona Pharma PLC American Depositary Shares (VRNA) "Outperform" Rating Reiterated at WedbushVerona Pharma PLC American Depositary Share's (VRNA) "Outperform" Rating Reiterated at Wedbush
www.americanbankingnews.com - September 8 at 10:44 AM
Brokerages Expect Verona Pharma PLC American Depositary Share (VRNA) to Announce ($0.51) EPSBrokerages Expect Verona Pharma PLC American Depositary Share (VRNA) to Announce ($0.51) EPS
www.americanbankingnews.com - August 17 at 4:48 AM
Q3 2017 Earnings Estimate for Verona Pharma PLC American Depositary Share (VRNA) Issued By WedbushQ3 2017 Earnings Estimate for Verona Pharma PLC American Depositary Share (VRNA) Issued By Wedbush
www.americanbankingnews.com - August 16 at 6:26 AM

SEC Filings

Verona Pharma (NASDAQ:VRNA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Verona Pharma (NASDAQ:VRNA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Verona Pharma (NASDAQ VRNA) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.